Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
批准号:
7905080
负责人:
Zhilei Chen
金额:
$13.77万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2011-07-31
关键词:
AddressAntiviral AgentsBe++ elementBerylliumBindingBiological ProcessCell CommunicationCell Culture TechniquesCell LineCell SurvivalCellsCessation of lifeChronic Hepatitis CCirrhosisClinical TrialsComplexComplex MixturesCultured CellsDevelopmentDrug Delivery SystemsDrug Metabolic DetoxicationEffectivenessElementsEscape MutantFutureGenesGeneticGenomeGenomic LibraryGoalsHarvestHepatitis CHepatitis C AntiviralHepatitis C TherapyHepatitis C virusIndividualInterferonsLeadLeftLentivirus VectorLibrariesLife Cycle StagesLiverLiver FailureMediatingMembrane ProteinsMethodologyMolecularNonstructural ProteinNucleic AcidsPeptide HydrolasesPeptide Leader SequencesPeptidesPharmaceutical PreparationsPolymerasePreclinical Drug EvaluationPrimary carcinoma of the liver cellsProceduresProcessProteinsPublic HealthResearchRibavirinRiskSeveritiesStagingSystemTaxesTherapeutic AgentsTimeViralVirusVirus InhibitorsVirus ReplicationWorkanti-hepatitis Cbasecostcytotoxicitydesigndrug candidatedrug developmenteffective therapyfrontiergenetic elementglobal healthhepatoma cellinhibitor/antagonistinnovationinterestliver transplantationmembermimeticsnovelparticleprogramsprotective effectpublic health relevanceresponsesmall hairpin RNAviral resistancevirus geneticsvirus host interaction
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) infection is a major public health problem, putting infected individuals (~180 million worldwide) at risk of developing cirrhosis, hepatocellular carcinoma, and liver failure. Chronic hepatitis C is the leading cause for liver transplantation. Current standard interferon-based therapy, a costly and time-consuming process, has only a ~50% cure rate, and no anti-HCV drugs have yet been approved for hepatitis C therapy. Despite the promise shown by HCV-specific proteases and polymerases as drug targets, the rapid emergence of viral resistance indicates that additional targets and combinations of antivirals will be necessary for effective treatment. We propose to isolate genetic suppressor elements (GSEs) from a library comprising a fragmented HCV genome which could be used both as potent anti-HCV therapeutic agents and as probes to identify and validate new targets for further drug screening. GSEs are nucleic acid or protein/peptide molecules derived from a gene or genome that act as transdominant inhibitors of a particular biological function through a variety of mechanisms, which includes binding to and blocking essential interaction surfaces for protein activity. In order to identify GSEs from within the HCV genome that exert inhibitory activity against HCV, a novel function-based selection system will be developed and implemented. Briefly, a fragmented HCV genome will be delivered to a hepatoma derivative cell line that is sensitive to a cytopathic effect exerted by HCV. The cells containing the HCV-derived genetic fragments will be subjected to a cytopathic challenge by exogenously administered cell culture-derived HCV (HCVcc) infectious particles, and cells surviving this HCV challenge will be enriched in GSEs that exert an inhibitory effect against HCV. Iterative application of this selection procedure will result in the identification of highly potent GSEs that protect cells against HCV infection and cytotoxicity. Preliminary studies will evaluate the degree of the protective effect conferred by the identified GSEs against HCV-mediated cytotoxicity, and the stage in the HCV life cycle at which the anti-HCV effect of the GSEs is exerted. Future studies originating from the identified GSEs are expected to reveal the molecular basis of the anti-HCV GSE activity, thus providing new leads for anti-HCV drug development. It is expected that the GSEs identified from the proposed research, and molecular mimetics derived therefrom, will inhibit HCV infection/propagation through diverse mechanisms, including the inhibition of virus-host cell interactions, thus contributing to the urgent quest for new and effective HCV antivirals on multiple fronts. PUBLIC HEALTH RELEVANCE: Infection by hepatitis C virus is a serious global health problem that causes numerous debilitating liver conditions. The current treatment regime for hepatitis C is time-consuming, expensive, and often ineffective, creating an urgent need for new and effective drugs. Novel anti-hepatitis C genetic suppressor elements isolated from this research will serve both as hepatitis C drugs, and as keys to open doors to new avenues of research in hepatitis C antiviral development.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1021/cb4004089
发表时间:
2013-12-20
期刊:
ACS chemical biology
影响因子:
4
作者:
[Simeon RL, Chamoun AM, McMillin T, Chen Z]
通讯作者:
Chen Z
DOI:
10.1002/hep.28028
发表时间:
2015-12-01
期刊:
Hepatology (Baltimore, Md.)
影响因子:
--
作者:
[Chen, Zhilei, Rice, Charles M]
通讯作者:
Rice, Charles M
Oral Protein Therapeutics Against C. difficile Associated Colitis
-
批准号:10455793
-
项目类别:
-
资助金额:$74.77万
-
财政年份:2021
-
负责人:Zhilei Chen
-
依托单位:
A Novel Technology for Engineering Binders to Membrane Proteins
-
批准号:10040547
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2020
-
负责人:Zhilei Chen
-
依托单位:
A Novel Technology for Engineering Binders to Membrane Proteins
-
批准号:10227122
-
项目类别:
-
资助金额:$18.94万
-
财政年份:2020
-
负责人:Zhilei Chen
-
依托单位:
Internal Toxin Neutralizer for Treating STEC-infection
-
批准号:9886184
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2019
-
负责人:Zhilei Chen
-
依托单位:
Artificial Ecology Sink as prophylaxis against viral infection
-
批准号:9348755
-
项目类别:
-
资助金额:$222.75万
-
财政年份:2017
-
负责人:Zhilei Chen
-
依托单位:
Broadly neutralizing non-antibody protein for treating clostridium difficile infection
-
批准号:9293991
-
项目类别:
-
资助金额:$22.51万
-
财政年份:2016
-
负责人:Zhilei Chen
-
依托单位:
Broadly neutralizing non-antibody protein for treating clostridium difficile infection
-
批准号:9167525
-
项目类别:
-
资助金额:$19.94万
-
财政年份:2016
-
负责人:Zhilei Chen
-
依托单位:
Isolation of Genetic Suppressor Elements Against Hepatitis C Virus
-
批准号:7708619
-
项目类别:
-
资助金额:$22.48万
-
财政年份:2009
-
负责人:Zhilei Chen
-
依托单位:
海外基金